Recruiting Lung Cancer Studies in Pittsburgh
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors....
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector that is designed to stimulate an anti-tumor immune response through the pro...
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
This study is a rolling arm study of investigational agents as monotherapy or in combination with pembrolizumab in participants with anti-programmed cell death 1 (PD-1)/ programmed cell death ligand 1...
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of...
Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )
This study aims to determine safety, tolerability, recommended phase 2 dose (RP2D), and preliminary antitumor activity of 225Ac-SSO110 with standard of care (SoC) therapy in patients with somatostatin...
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
This is a Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with First-Line Osi...
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
This phase II clinical trial will study the safety and efficacy of onvansertib to treat patients with small cell lung cancer (SCLC) who have either not responded to or are unable to tolerate chemother...
About Lung Cancer Clinical Trials in Pittsburgh
Lung cancer is the leading cause of cancer death worldwide, starting in the cells of the lungs. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatments include surgery, chemotherapy, radiation, immunotherapy, and targeted drugs.
There are currently 7 lung cancer clinical trials recruiting participants in Pittsburgh, PENNSYLVANIA. These studies are seeking a combined 746 participants. Research is being sponsored by Bristol-Myers Squibb, Krystal Biotech, Inc., Merck Sharp & Dohme LLC and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Lung Cancer Clinical Trials in Pittsburgh — FAQ
Are there lung cancer clinical trials in Pittsburgh?
Yes, there are 7 lung cancer clinical trials currently recruiting in Pittsburgh, PENNSYLVANIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Pittsburgh?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Pittsburgh research site will contact you about next steps.
Are clinical trials in Pittsburgh free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Pittsburgh studies also compensate for your time and travel.
What lung cancer treatments are being tested?
The 7 active trials in Pittsburgh are testing new therapies including novel drugs, biologics, and treatment approaches for lung cancer.
Data updated March 2, 2026 from ClinicalTrials.gov